Description: Biosolution Co., Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers a spray type autologous keratinocyte therapy for wounds under the brand name of KeraHeal; and thermosensitive hydrogel-type allogeneic keratinocyte therapy product under the brand name of KeraHeal-Allo. It provides human tissue models; human-derived primary cells for experimental purposes, which includes adult human epidermal keratinocyte, adult human dermal fibroblast, and human umbilical vein endothelial cells; and raw materials for cosmeceutics. In addition, the company offers alternative testing services to animal testing on drugs, cosmetics, household items, and their raw materials; and quality control testing services for drugs, including sterility, micro plasma, adventitious virus, endotoxin, and other quality tests. It is also developing CartiLife, a small spherical autologous chondrocyte therapy product, which is in Phase II clinical trial for the treatment of arthritis. The company was formerly known as MCTT Bio Co., Ltd. and changed its name to Biosolution Co., Ltd. in January 2016. Biosolution Co., Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
Home Page: www.biosolutions.co.kr
Seoul Technopark
Seoul,
South Korea
Phone:
82 2 3446 8884
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 21.3189 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 71 |